Unrecognized ingestion of toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America

Clinical Infectious Diseases

Volumn 53, Issue 11, 2011, Pages 1081-1089

  Boyer, Kenneth ^a,b   Hill, Dolores ^c   Mui, Ernest ^a   Wroblewski, Kristen ^d   Karrison, Theodore ^d   Dubey, J P ^c   Sautter, Mari ^a   Noble, A Gwendolyn ^a   Withers, Shawn ^d   Swisher, Charles ^e   Heydemann, Peter ^a,b   Hosten, Tiffany ^a   Babiarz, Jane ^a   Lee, Daniel ^a   Meier, Paul ^d,f   McLeod, Rima ^a,d,g  

^a Department of Pediatrics ^*  (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f Howard Hughes Medical Institute   (United States)

^g MICHAEL REESE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONGENITAL TOXOPLASMOSIS; EPIDEMIC; FEMALE; FOOD CONTAMINATION; HIGH RISK INFANT; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MATERNAL SERUM; OOCYST; PERINATAL INFECTION; PRENATAL EXPOSURE; PRIMARY INFECTION; PRIORITY JOURNAL; SPOROZOITE; TOXOPLASMA GONDII; WATER CONTAMINATION;

ADULT; ANTIBODIES, PROTOZOAN; CLINICAL LABORATORY TECHNIQUES; EATING; FEMALE; FOOD CONTAMINATION; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; NORTH AMERICA; OOCYSTS; PREGNANCY; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL;

EID: 80755136920     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir667     Document Type: Article

References (32)

1. Boyer K, Holfels E, Roizen N, et al. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. Am J Obstet Gynecol 2005;192:564-71. (Pubitemid 40214997)
2. Hill D, Coss C, Dubey JP, et al. Identification of a sporozoite-specific antigen fromToxoplasma gondii. J Parasitol 2011;97:328-37.
3. Lelong M, Bernard J, Desmonts G, Couvreur J. Acquired toxoplasmosis. Arch Fr Pediatr 1960;17:281-331.
4. Teutsch SM, Juranek DD, Sulzer A, Dubey JP, Sikes RK. Epidemic toxoplasmosis associated with infected cats. N Engl J Med 1979;300:695-9. (Pubitemid 9154805)
5. Burnett AJ, Shortt SG, Isaac-Renton J, King A, Werker D, Bowie WR. Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology 1998;105:1032-7. (Pubitemid 28268327)
6. McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob Agents Chemother 1992;36:1040-8.
7. McGee T, Wolters C, Stein L, et al. Absence of sensorineural hearing loss in treated infants and children with congenital toxoplasmosis. Otolaryngol Head Neck Surg 1992;106:75.
8. Swisher C, Boyer K, McLeod R. Neurologic findings in congenital toxoplasmosis. Ann Neurol 1992;32:448.
9. McAuley J, Boyer K, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994;18:38-72. (Pubitemid 24025917)
10. Roizen N, Swisher C, Stein M, et al. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 1995;95:11-20.
11. Patel DV, Holfels EM, Vogel NP, et al. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology 1996;199:433-40. (Pubitemid 26121990)
12. Mets M, Holfels E, Boyer K, et al. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol 1996;122:309-24. (Pubitemid 26300047)
13. Roizen N, Kasza K, Karrison T, et al. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Pediatrics 2006;118:e379-90. (Pubitemid 46090508)
14. Mack D, Johnson J, Roberts F, et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999;29:1351-8. (Pubitemid 29528124)
15. Delair E, Latkany P, Noble AG, Rabiah P, McLeod R, Brézin A. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm 2011;19:91-102.
16. McLeod R, Boyer K, Karrison T, et al. Outcomes of treatment of congenital toxoplasmosis, 1981-2004, the National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS). Clin Infect Dis 2006;42:1383-94.
17. Arun V, Noble AG, McLeod R. Cataracts in congenital toxoplasmosis. J AAPOS 2007;11:551-4. (Pubitemid 350251240)
18. Jamieson SE, de Roubaix LA, Cortina-Borja M, et al. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One 2008;3:e2285.
19. Benevento J, Jager R, Noble AG, et al. Toxoplasmosis associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol 2008;126:1152-5.
20. Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. Am J Ophthalmol 2008;146:375-84.
21. Remington JS, McLeod R, Thulliez P, Desmonts G. Toxoplasmosis. In: Infectious diseases of the fetus and newborn infant. 6th ed. Remington JS, Klein JO, eds. Philadelphia. PA: WB Saunders, 2006;947-1091.
22. Phan L, Kasza K, Jalbrzikowski J, et al. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology 2008;115: 553-9.e8.
23. McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H. Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz 2009;104:320-44. ISSN 0074-276.
24. Jamieson SE, Cordell H, Petersen E, McLeod R, Gilbert RE, Blackwell JM. Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo Cruz 2009;104:162-9.
25. Witola WH, Mui E, Hargrave A, et al. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun 2011;79:756-66.
26. Cong H,Mui E,WitolaWH, et al. Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLAA*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD81T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res 2010;6:12.
27. Lees MP, Fuller SJ, McLeod R, et al. P2X7 receptor-mediated killing of an intracellular parasite, Toxoplasma gondii, by human and murine macrophages. J. Immunol 2010;184:7040-6.
28. Frenkel JK, Jacobs L. Ocular toxoplasmosis;pathogenesis, diagnosis and treatment. AMA Arch Ophthalmol 1958;59:260-79.
29. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945;1:80-3.
30. StataCorp. Stata statistical software: release 10. College Station, TX: StataCorp LP, 2007.
31. Levy JK, Crawford PC. Humane strategies for controlling feral cat populations. J Am Vet Med Assoc 2004;255:1354-60. (Pubitemid 39441715)
32. Hill DE, Chirukandoth S, Dubey JP. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res Rev 2005;6:41-61.